logo

Jounce Therapeutics, Inc. (JNCE)



Trade JNCE now with
  Date
  Headline
9/1/2020 8:34:58 AM Gilead Sciences And Jounce Therapeutics Announce License Deal for Novel Immunotherapy Program
1/23/2020 8:03:30 AM Jounce Therapeutics Appoints Robert Iannone To Its Board
7/23/2019 6:05:08 PM Jounce Therapeutics Updates On Strategic Collaboration With Celgene
4/3/2019 8:11:52 AM Jounce Therapeutics Presents Preclinical Data From JTX-8064 Program At 2019 AACR Annual Meeting
3/6/2019 6:40:07 AM Jounce Therapeutics Q4 Net Loss $2.0 Mln Or $0.06/Shr Vs $9.4 Mln Or $0.29/Shr Last Year
1/3/2019 8:08:46 AM Jounce Therapeutics Completes Enrollment In First Cohort For Its Phase 1 Dose Escalation Clinical Trial Of JTX-4014
11/13/2018 6:46:41 AM Jounce Therapeutics Q3 Net Loss $7.6 Mln Or $0.23/Shr Vs Loss $4.1 Mln Or $0.13/Shr Last Year
8/9/2018 6:36:31 AM Jounce Therapeutics Q2 Net Loss $4.7 Mln Or $0.14/Shr Vs Loss $3.4 Mln Or $0.11/Shr Last Year